Primary focal segmental glomerulosclerosis

This phase 2 trial tested the drug obinutuzumab in 20 adults with a kidney disease called primary FSGS. The participants had not responded well to or could not take standard treatments like steroids. The goal was to see if obinutuzumab could reduce protein leakage in the urine, a…

This Phase 3 trial tested whether sparsentan, a drug that blocks two pathways involved in kidney damage, can better protect kidney function than the standard treatment irbesartan in people with focal segmental glomerulosclerosis (FSGS). The study enrolled 371 adults and children …

This study tested an experimental drug called R3R01 in 43 people with two rare kidney diseases (Alport syndrome and focal segmental glomerulosclerosis) whose protein in urine remained high despite standard treatment. The main goals were to check safety and see if the drug could r…

This study tested a new wearable patch that collects sweat to measure sodium and creatinine levels, which are important for monitoring kidney health and dehydration. Five adults with kidney disease wore the patch while their sweat was analyzed using a special light-based techniqu…